Advancing Life-Changing Discoveries in Neuroscience

Neurocrine Biosciences (Nasdaq: NBIX)
Q4 and Year-End 2024 Earnings Presentation
February 6, 2025

NEUROCRINE® BIOSCIENCES
You Deserve Brave Science®

Safe Harbor and Forward-Looking Statements

In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully launching CRENESSITY; our financial and operating performance, including our future revenues, expenses, or profits; our collaborative partnerships; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general; risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this presentation after the date hereof other than as required by law

In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this presentation also contains the following Non-GAAP financial measures: Non-GAAP R&D expense, Non-GAAP SG&A expense, and Non-GAAP net income and net income per share. When preparing the Non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these Non-GAAP financial measures exclude: non-cash stock-based compensation expense, charges associated with convertible senior notes, vacated legacy campus facility costs, net of sublease income, non-cash amortization expense related to acquired intangible assets, acquisition and integration costs, changes in fair value of equity investments, changes in foreign currency exchange rates and certain adjustments to income tax expense. These Non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these Non-GAAP financial measures help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these Non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&D and SG&A expenses on both a GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to Non-GAAP financial results is included in the attached financial information

Where Are We Today?

Discovered and Developed Four Novel FDA-Approved Programs

Deep Expertise in Neuroscience Drug Development

Fully-Integrated Organization with R&D and Commercial Capabilities

Growing Blockbuster Commercial Product in **INGREZZA** with Strong IP

Future Blockbuster Opportunity with **CRENESSITY**

Industry-Leading Portfolio of Muscarinic Compounds

Strong Financial Profile That Can Support Significant R&D Investment

Building a Leading Neuroscience-Focused Company

Neurocrine Discovered / Developed In the U.S.

INGREZZA® * (valbenazine) capsules

Crenessity™ (crinecerfont)

Orilissa® ‡ elagolix tablets 150 mg 200 mg

Oriahnn® ‡ elagolix, estradiol and norethindrone acetate capsules and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

In the U.S. and Europe

Alkindi® hydrocortisone granules in capsules for opening

In Europe

Efmody® Hydrocortisone modified-release hard capsules

NEUROCRINE® BIOSCIENCES

*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets
‡AbbVie has global commercialization rights

Well-Positioned for Sustained & Long-Term Growth

COMMERCIAL*

TARDIVE DYSKINESIA AND
HUNTINGTON'S DISEASE CHOREA

CLASSIC CONGENITAL
ADRENAL HYPERPLASIA

RESEARCH & DEVELOPMENT

- Neurology
- Neuroendocrinology
- Neuropsychiatry
- Neuroimmunology

Therapeutic Area Diversification

Robust and Sustainable Pipeline

Multiple Compounds in Mid- to Late-Stage Studies

Rapidly Growing Early-Stage Portfolio

STRONG FINANCIAL POSITION

$2.50 - $2.60 Billion

2025 INGREZZA
Annual Net Sales Guidance

~$1.8B

Cash and Investments as of 12/31/2024†

Strong Balance Sheet

Durable Cash Flows

Attractive P&L Profile

NEUROCRINE® BIOSCIENCES

*Products commercialized by Neurocrine Biosciences, Inc. in the U.S.
†On 10/31/24, Neurocrine entered into a $300 million accelerated share repurchase plan which terminated in the first quarter of 2025.

Our Pipeline Today – 12 Programs

Modality Key

Small Molecule

PROGRAM (TARGET)	MODALITY	THERAPEUTIC AREA	INDICATION	PHASE 1	PHASE 2	PHASE 3
valbenazine (VMAT2 Inhibitor)		Neuropsychiatry	Adjunctive Treatment of Schizophrenia			
valbenazine (VMAT2 Inhibitor)		Neurology	Dyskinetic Cerebral Palsy			
osavampator /NBI-'845 (AMPA)		Neuropsychiatry	Inadequate Response to Treatment in Major Depressive Disorder			
NBI-'568 (M4 Agonist)		Neuropsychiatry	Schizophrenia			
NBI-'770 (NMDA NR2B NAM)		Neuropsychiatry	Major Depressive Disorder			
NBI-'570 (M1/M4 Agonist)		Neuropsychiatry	Schizophrenia-CNS Indications			
NBI-'567 (M1 Agonist)		Neuropsychiatry	CNS Indications			
NBI-'569 (M4 Agonist)		Neuropsychiatry	CNS Indications			
NBI-'986 (M4 Antagonist)		Neurology	Movement Disorders			
NBI-'890 (VMAT2 Inhibitor)		Neuropsychiatry	CNS Indications			
NBI-'355 (Nav1.2/1.6)		Neurology	Epilepsy			
NBI-'675* (VMAT2 Inhibitor)		Neuropsychiatry	CNS Indications			

Industry-Leading Muscarinic Pipeline

Potential Areas for Development

Alzheimer's Disease • Bipolar Disorder
Lewy Body Dementia • Parkinson's Disease
Schizophrenia

Dystonia • Parkinson's Disease Tremor

NEUROCRINE® BIOSCIENCES

*Phase 1 Initiating in Q1

2024 Highlights and 2025 Key Milestones and Activities

2024 Highlights

- **INGREZZA® (valbenazine) Net Product Sales of ~$2.31B in 2024**
  - Represents ~$480 Million YoY Sales Growth, or 26% vs. 2023
  - Q4 2024 INGREZZA Net Sales of $615M Grew 23% vs. Q4 2023 Driven by Strong Underlying Demand and Improved Gross to Net Dynamics
  - Completed Salesforce Expansion to Help Accelerate Appropriate Diagnosis and Treatment of TD and HD Chorea
- **On December 13, FDA Approved CRENESSITY™ for the Treatment of Adults and Pediatric Patients with Classic Congenital Adrenal Hyperplasia**
  - Launched Product with 11 New Patient Treatment Forms Received in Less Than Two Full Weeks Before Exiting 2024
- **Reported Positive Phase 2 Results for:**
  - Osavampator / NBI-'845 (AMPA Potentiator) in Adults with Major Depressive Disorder (MDD)
  - NBI-'568 (M4 Agonist) for the Treatment of Schizophrenia
- **Initiated Phase 2 Study of NBI-'770 (NMDA NR2B NAM) in MDD**
- **Settled Convertible Notes Due in Q2 in Cash and Launched $300M Accelerated Share Repurchase Program in Q4**
- **Kyle W. Gano succeeds Kevin Gorman as CEO**

2025 Key Milestones and Activities

- **Deliver on INGREZZA Net Sales Guidance of $2.5 - $2.6B**
- **Successfully Launch CRENESSITY**
- **Report Mid-to-Late-Stage Top-Line Data for:**
  - Phase 3 Study of valbenazine for the Adjunctive Treatment of Schizophrenia
  - Phase 3 Study of valbenazine for Dyskinetic Cerebral Palsy
  - Phase 2 Study of NBI-'770 for the Treatment of MDD
- **Initiate Phase 3 Registrational Studies for:**
  - Osavampator as an Adjunctive Therapy for the Treatment of MDD
  - NBI-'568 for the Treatment of Schizophrenia
- **Initiate Phase 2 Study for:**
  - NBI-'568 for Bipolar Mania
  - NBI-'570 (Dual M1 / M4 Agonist) in Schizophrenia
- **Initiate Phase 1 Study for NBI-'675 (VMAT2 Inhibitor) for Movement Disorders**
- **Initiated Phase 1 Study for NBI-'355 (Na_V 1.2 / 1.6 Inhibitor) for Epilepsy**
- **Advance Internally Developed Pre-Clinical Programs Including Biologics (Peptides, Antibodies, Gene Therapies) into First-in-Human Studies**
- **Host R&D Day in Second Half of 2025**

TD = Tardive Dyskinesia; HD = Huntington's Disease; AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; M4 = M4 Muscarinic Receptor; NMDA NR2B NAM = n-methyl-d-aspartate Receptor Subtype 2B Negative Allosteric Modulator; M1 = M1 Muscarinic Receptor; VMAT2 = Vesicular Monoamine Transporter 2; Na_V = Sodium Channel

2024 Financial Summary

$ Millions, Except Non-GAAP Earnings Per Share

Item	2024	2023	Highlights / Comments
Revenue - Product Sales, Net - Collaboration Revenue	$2,355 $2,331 $25	$1,887 $1,861 $27	2024 INGREZZA Sales of ~$2.3B Represents YoY Growth of 26% vs. FY 2023
Non-GAAP R&D Expense	$662	$497	Increase Due to Support Expanded / Advancing Portfolio Including osavampator in Major Depressive Disorder, our Muscarinic Franchise and Preclinical R&D Activities
Non-GAAP SG&A Expense	$863	$757	Increase Due to Incremental Investment in CRENESSITY-Related Headcount and Pre-Launch Activities, and Continued Investment in INGREZZA, Including the Recent Expansion of our Psychiatry / Long-Term Care Sales Teams in September 2024
Non-GAAP Net Income	$656	$390	Increase Driven by Higher INGREZZA Sales and Decreased Total Payments for Upfront Fees / Development Milestones Achieved in Connection with Collaborations Partially Offset by Increase in Investments Outlined Above in SG&A and R&D
Non-GAAP Earnings per Share, Diluted	$6.33	$3.86	YoY Growth of 64% vs. 2023
Cash and Investments (Period End)	$1,816	$1,719	2024 Cash Outflow Includes: - $309M for Settlement of Outstanding 2024 Notes in May 2024 - $300M for Accelerated Share Repurchase Program in October 2024

NEUROCRINE® BIOSCIENCES

All income statement items, except revenue, are non-GAAP financial measures; see reconciliations accompanying the presentation. All numbers except EPS rounded to the nearest million.

Q4 2024 Financial Summary

$ Millions, Except Non-GAAP Earnings Per Share

Item	Q4 2024	Q4 2023	Highlights / Comments
Revenue - Product Sales, Net - Collaboration Revenue	$628 $621 $7	$515 $507 $8	INGREZZA Sales of $615M Represents YoY Growth of 23% Driven by Strong Underlying Patient Demand and Improvement in Gross-to-Net Dynamics
Non-GAAP R&D Expense	$164	$124	Increase Due to Support Expanded / Advancing Portfolio Including osavampator in Major Depressive Disorder, our Muscarinic Franchise and Preclinical R&D Activities
Non-GAAP SG&A Expense	$242	$194	Increase Due to Incremental Investment in CRENESSITY-Related Headcount and Pre-Launch Activities, and Continued Investment in INGREZZA, Including Recent Expansion of our Psychiatry / Long-Term Care Sales Teams in September 2024
Non-GAAP Net Income	$173	$158	Increase Driven by Higher INGREZZA Sales Partially Offset by Incremental Operating Expenses
Non-GAAP Earnings per Share, Diluted	$1.69	$1.54	YoY Growth of ~10%
Cash and Investments (Period End)	$1,816	$1,719	Q4 2024 Cash Outflow Includes $300M for Accelerated Share Repurchase Program in October 2024

NEUROCRINE® BIOSCIENCES

All income statement items, except revenue, are non-GAAP financial measures; see reconciliations accompanying the presentation. All numbers except EPS rounded to the nearest million.

2025 INGREZZA Net Sales and Expense Guidance

Item ($ Millions)	2024 Actuals	2025 Guidance Range
INGREZZA Net Product Sales[1]	$2,314	$2,500 - $2,600
GAAP R&D Expense[2]	$731	$960 - $1,010
Non-GAAP R&D Expense[2, 3]	$662	$890 - $940
GAAP SG&A Expense[4]	$1,007	$1,110 - $1,130
Non-GAAP SG&A Expense[3, 4]	$863	$955 - $975

1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.
2. R&D guidance reflects the continued advancement of our pre-clinical and clinical portfolio including the initiation of our Phase 3 programs for osavampator in MDD and NBI-568 in schizophrenia. R&D guidance includes $60 million of expense for development milestones primarily in connection with our collaborations with Takeda and Nxera achieved or deemed probable to achieve. Acquired in-process research and development expense is included in guidance once significant collaboration and licensing arrangements have been completed.
3. Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $70 million in R&D and $130 million in SG&A and vacated legacy campus facility costs.
4. SG&A guidance range reflects expense for ongoing commercial initiatives supporting INGREZZA growth and the launch of CRENESSITY.

Corporate Sustainability: “A” Rating at MSCI and Rank in 11th Percentile for Biotech at Sustainalytics



Our Purpose: Relieve Suffering for People with Great Needs

Adhere to the highest product quality and safety standards

Comprehensive Quality System that aligns with:

- Good Manufacturing Practices (GMP)
- Good Laboratory Practices (GLP)
- Good Clinical Practices (GCP)

Invest in our people and communities

Industry-leading employee engagement and diversity

- Top decile employee engagement among biopharmaceutical peers
- Gender and racial/ethnic diversity above biotech industry benchmark*

Minimize our impact on the environment

Improving profitability and yields through green chemistry

- ~30% improvement in yields
- ~65% reduction in waste
- ~65% reduction in water use

*According to a study by the Biotechnology Innovation Organization

Click here to see Neurocrine’s 2024 ESG Report

NEUROCRINE BIOSCIENCES

NEUROCRINE® BIOSCIENCES

Our Medicines, Our Patients

INGREZZA®
(valbenazine) capsules

NEUROCRINE® BIOSCIENCES

INGREZZA Quarterly Net Sales Performance



NEUROCRINE® BIOSCIENCES

Substantial Impact on TD Patients and Care Partners

Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications

Uncontrollable, abnormal and repetitive movements



>50%

of patients experience meaningful emotional, social and psychological impact*

Job Performance

Patients believe TD affects their ability to perform their job

Low Self-Worth

Psychiatric patients may already have difficulty gaining stability and social acceptance

Isolation

Loss of physical control may make patients more likely to withdraw from social situations

* https://www.takeontd.com/ *Source: IQVIA's SMART Audit, Quarterly Data for Antipsychotic Class*

NEUROCRINE® BIOSCIENCES

Nascent Tardive Dyskinesia Market Presents Significant Opportunity

ESTIMATED TO AFFECT

~800,000

people in the U.S.

Source: U.S.Claims Data and 31 Global Scientific Publications;
U.S. Tardive Dyskinesia Prevalence Estimates Updated Biannually; Last Update in October 2024

Increasing Antipsychotic Prescriptions (U.S.)



Nearly 9 of 10

TD PATIENTS ARE NOT CURRENTLY TREATED WITH A VMAT2 INHIBITOR LIKE INGREZZA



NEUROCRINE® BIOSCIENCES

Sources: Neurocrine Biosciences Quarterly Data, IQVIA SMART
VMAT2 = Vesicular Monoamine Transporter 2

INGREZZA® Approved by the FDA for the Treatment of Chorea Associated with Huntington's Disease

INGREZZA

Simple once-a-day treatment targeted for symptom control of chorea movements

Safety profile consistent with and supported by **extensive safety** data in tardive dyskinesia

In randomized, double-blind, placebo-controlled KINECT-HD study, **treatment with valbenazine resulted in a placebo-adjusted mean reduction in the TMC* score of 3.2 units ($p < 0.0001$)**



Chorea affects

~90% of the 40,000

patients with HD in the U.S.

Rare neurodegenerative disorder in which neurons within the brain break down

Patients develop involuntary abnormal, abrupt or irregular movements

INGREZZA makes dosing **SIMPLE from the start**

- ✓ No complex dose adjustments
- ✓ 1st dose is an efficacious dose
- ✓ ALWAYS one capsule, once daily
- ✓ Taken any time with or without food
- ✓ Can be added to most stable mental health regimens

NEUROCRINE® BIOSCIENCES

* TMC = Total Maximal Chorea

Crenessity™
(crinecerfont)

NEUROCRINE® BIOSCIENCES

CRENESSITY Offers Potential to Change Standard of Care

First New Treatment Available for Classic CAH in 70 Years

Crenessity™ (crinecerfont)

ABOUT CRENESSITY

- First medication approved as an **adjunct treatment to glucocorticoid replacement to control androgens in adult and pediatric patients ages 4+** with classic congenital adrenal hyperplasia (CAH)
- Approved December 13, 2024 after **three decades of research in CRF**
- Supported by data from the **largest-ever clinical trial program** in pediatric and adults with classic CAH
- Launched Mid-December in U.S. with **Significant Level of Enthusiasm and Excitement** Across Endocrinology Provider and CAH Patient / Family Communities

ABOUT CAH

- **Rare and lifelong genetic condition** that affects approximately **30,000 people in the U.S**.
- Caused by variants of the CYP21A2 gene that leads to **deficiency of the enzyme 21-hydroxylase** leading to **uncontrolled and high levels of ACTH and adrenal androgens**
- Identified at or soon after birth; can lead to **life-threatening adrenal crisis and androgen excess**
- For the past **70 years, steroids have been the only option** to replace missing cortisol and address excess androgens

NEUROCRINE® BIOSCIENCES

Neuropsychiatry Pipeline

Osavampator* (AMPA Potentiator): Reported Positive Phase 2 Top-Line Study Results in Adults with Major Depressive Disorder

Inadequate Response to Treatment in Major Depressive Disorder (MDD)

~1/3 of the 16 million+ people in the U.S. who live with MDD do not respond to available antidepressants.

MDD symptoms are characterized by a persistently depressed mood or loss of interest in daily activities that can impact normal daily functioning, relationships, and overall quality of life.

Current treatments range from selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and antidepressants along with behavioral therapy.

osavampator (previously NBI-’845)

Potent first-in-class AMPA potentiator

- Oral
- Once daily

Antidepressant effects may be mediated by activation of AMPA and resultant downstream pathways

Phase 2 SAVITRI Study:

- Met primary endpoint with statistically significant reduction in MADRS total score at day 28
- Met key secondary endpoints, including statistically significant reduction in MADRS total score at day 56
- NBI-’845 was generally well-tolerated

Next Steps: Initiating Two Additional Phase 3 Registrational Study in MDD

- Initiated first of three total MDD studies in Q1 2025
- Sharing additional Phase 2 study details later in 2025

Neurocrine Holds Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator

NEUROCRINE® BIOSCIENCES

* Osavampator is investigational and not approved in any country

AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; MADRS = Montgomery Åsberg Depression Rating Scale

Osavampator* (AMPA Potentiator) SAVITRI™ Phase 2 Study Summary Results

EFFICACY

- The study met its primary and key secondary endpoints
- Once-daily, oral administration of NBI-'845 produced a statistically significant change from baseline in Montgomery Åsberg Depression Rating Scale (MADRS) total score at both Day 28 (primary) and Day 56 (secondary).

Least Squares Mean Change From Baseline in MADRS for Statistically Significant NBI-'845 Dose



SAFETY AND TOLERABILITY

- NBI-1065845 was generally well-tolerated
- Most common adverse event was headache, of which, a majority were transient and mild in severity
- Adverse event profile for both doses of NBI-1065845 were comparable to placebo
- No seizures, deaths, or serious adverse events
- No psychotomimetic or dissociative events throughout the study
- Discontinuation rates were low throughout the study

NEUROCRINE® BIOSCIENCES * Osavampator is investigational and not approved in any country

Muscarinic Platform Includes Multiple Clinical Programs

From M1 to M4 Selective Orthosteric Agonists

M1
"Cognition"

PREFERRING

SELECTIVE

M1/M4
DUAL

- **Phase 1**
- **Advancing to Phase 2 in Schizophrenia in 2H 2025**

PREFERRING

M4
"Psychosis"



SELECTIVE

- **Completed Phase 2 Study**
- **Advancing to Phase 3 in Schizophrenia in 1H 2025**

NEUROCRINE BIOSCIENCES

Combination Therapy to Block Off-target Effects Avoided

Acetylcholine Cooperativity Not Required

Summary of NBI-’568* Positive Phase 2 Topline Results

Once-Daily 20mg Dose: Efficacy, Safety, and Tolerability Results **Support Advancement to Phase 3 in 1H 2025**

20mg Once-daily Demonstrated Statistically Significant and Clinically Meaningful Improvements Across Primary and Additional Endpoints

- **PANSS Total Score Change: -18.2**
- **PANSS Total Score Change vs. Placebo: -7.5 (p=0.011)**
- **Effect Size: 0.61**
- **CGI-S Change vs. Placebo: -0.7 (p<0.001)**
- **Marder Factor Score Change vs. Placebo:**
  - ***Positive:* -3.0 (p=0.004)**
  - ***Negative:* -1.9 (p=0.028)**

Generally Safe and Well-tolerated Across All Doses Tested

- Treatment discontinuation rates due to adverse events were similar between NBI-’568 and placebo
- Adverse events with the highest incidence were somnolence, dizziness, and headache
- Nausea, constipation and other gastrointestinal adverse events were low in frequency and similar to placebo
- NBI-’568 was not associated with a greater increase in weight than placebo

Efficacy, Safety and Tolerability Profile Combined With Once-daily Dosing Supports Advancement to Phase 3 Development

- Initiating Phase 3 registrational studies in Schizophrenia in first half of 2025
- Initiating Phase 2 study in Bipolar Mania in second half of 2025
- Evaluating additional indications for NBI-’568
- Advancing follow-on compounds in muscarinic agonist portfolio including NBI-’570 (dual M1 / M4 agonist)

NEUROCRINE® BIOSCIENCES

* NBI-’568 is investigational and not approved in any country
PANSS = Positive & Negative Syndrome Scale; P-values are one-sided. Effect size (Cohen’s D) is based on observed data.

Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6



20mg QD Efficacy Data
Week 4 – Week 6

Week	4	5	6**
PANSS Total Score			
LS Mean[1]	-16.4	-20.2	-18.2
LS Mean Difference vs. Placebo[1]	-6.8 p = 0.008	-10.0 p < 0.001	-7.5 p = 0.011
Effect Size[2]	0.53	0.72	0.61

*** Primary Endpoint = Week 6*

[1] Least-squares (LS) means are from a MMRM which includes treatment group, visit, and study period as fixed effects; treatment group-by-visit interaction; baseline PANSS total score as a covariate; and subject as a random effect.
[2] Effect size (Cohen's D) is based on observed data.

Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints

Week 6	CGI-S		Marder Factor — Positive		Marder Factor — Negative	
	Placebo N=68	20mg QD N=35	Placebo N=68	20mg QD N=35	Placebo N=68	20mg QD N=35
LS Mean Change from Baseline*	-0.5	-1.2	-2.8	-5.8	-1.2	-3.1
LS Mean Difference vs. Placebo*		-0.7 p < 0.001		-3.0 p = 0.004		-1.9 p = 0.028

*Least-squares (LS) means are from a MMRM which includes treatment group, visit, and study period as fixed effects; treatment group-by-visit interaction; baseline value as a covariate; and subject as a random effect.

NBI-’568 Was Generally Safe and Well Tolerated at All Doses Studied

Treatment-Emergent Adverse Events Occurring in ≥ 5% of NBI-'568 All Treated Group

	Placebo N=70	20mg QD N=40	40mg QD N=39	60mg QD N=34	30mg BID N=27	All Treated N=140
Somnolence	2 (2.9)	5 (12.5)	2 (5.1)	7 (20.6)	1 (3.7)	15 (10.7)
Dizziness	1 (1.4)	5 (12.5)	3 (7.7)	4 (11.8)	1 (3.7)	13 (9.3)
Headache	14 (20.0)	1 (2.5)	5 (12.8)	1 (2.9)	5 (18.5)	12 (8.6)
Nausea	2 (2.9)	2 (5.0)	3 (7.7)	3 (8.8)	0	8 (5.7)
Constipation	2 (2.9)	2 (5.0)	3 (7.7)	1 (2.9)	1 (3.7)	7 (5.0)

5.0% Treatment Discontinuation Rate Due to Adverse Events Across All NBI-'568 Arms vs. 4.3% For Placebo

NEUROCRINE® BIOSCIENCES

NBI-’568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development

Type of Muscarinic Activation	Subtype Selectivity	Requires Endogenous Ligand (Acetylcholine)
Pan Agonism	**Low** Targets M1-M5	**No**
Positive Allosteric Modulation	**High** Targets only M4	**Yes**
Selective Agonism (NBI-'568)	**High** Targets only M4 >500-fold agonist selectivity for the M4 receptor over other muscarinic receptors	**No**

Large Opportunity For NBI-'568, A Novel And Differentiated Asset

With no reliance on innate acetylcholine levels, NBI-'568 is the **first and only highly selective orthosteric M4 agonist**, potentially introducing a **new modality for treatment.**

NBI-'568 potentially offers a compelling and competitive benefit-risk profile

Convenience of **once-daily dosing with or without food**

Increased conviction in **indication expansion opportunities** for NBI-'568 and Neurocrine’s muscarinic portfolio

NBI-’568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics

Clinical-Stage Muscarinic Programs



Sites	12	5	22	15	30
Randomization Ratio (active:placebo)	1:1	2:1	1:1	2:1	1:1
Weeks of Treatment	5	6	5	6	5
Date	Nov ‘19	Jun ’21	Aug ’22	Aug ’24	Mar ‘23

Leading Approved Treatments



Source: 1. Brannan S, et al. N Engl J Med. 2021;384(8):717-726. 2. Krystal J, et al. Lancet. 2022;400(10369):2210–2220. 3. Kaul I, et al. Lancet. 2024;403(10422):160–170. 4. Kaul I, et al. JAMA Psychiatry. 2024;81(8):749-756. 5. Huhn M, et al. Lancet. 2019;394(10202):939-951. 6. Correll CU, et al. JAMA Psychiatry. 2020;77(4):349-358.

NEUROCRINE BIOSCIENCES

Valbenazine*: Phase 3 Study for the Adjunctive Treatment of Schizophrenia with Top-Line Data in 2025

Adjunctive Treatment of Schizophrenia (ATS)

Schizophrenia is one of the **leading causes of disability** worldwide, affecting **up to 3.5M people** in the U.S. alone.

A serious, chronic mental illness that causes **abnormal thoughts, feelings and actions**.

Estimated that ~30% of patients with schizophrenia in the U.S. do not adequately respond to antipsychotic therapy, underscoring a **clear unmet need for improved pharmacological approaches**.

ATS Study Informs Development of Next-Generation VMAT2 Inhibitors Including NBI-’890 (In Phase 1) and NBI-’675 (Entering Phase 1 in Q1 2025)

*Valbenazine for ATS is investigational and not approved in any country

NEUROCRINE® BIOSCIENCES

Neurology Pipeline

Neurology Programs in Clinical Development

Valbenazine*

- VMAT2 Inhibitor
- Ongoing Phase 3 Study in Dyskinetic Cerebral Palsy
- Top-Line Data Readout in 2025
- Dyskinetic Cerebral Palsy
  - ✓ Form of Cerebral Palsy (CP)
  - ✓ Affects ~15% of the approximately 500K to 1M people in the U.S. diagnosed with the CP
  - ✓ Can result in a range of developmental delays, physical difficulties and involuntary muscle movements.
  - ✓ No approved treatments

NBI-'890*

- Next Generation VMAT2 Inhibitor
  - ✓ High Potency / Low Solubility Are Required for a Long-Acting Injectable Clinical Candidate
- Ongoing Phase 1 Study
- Studied for Central Nervous System Indications
- Internally Developed Candidate

NBI-'355*

- Selective $Na_v1.2$ / $Na_v1.6$ Inhibitor
- Recently Initiated Phase 1 Study
- Studied as a Potential Treatment for Several Forms of Epilepsy in Adult and Pediatric Patient Populations
- $Na_v1.2$ / $Na_v1.6$
  - ✓ Two Predominant Excitatory Voltage-Gated Sodium Channels in the CNS
  - ✓ Malfunctions in These Ion Channels Cause Irregular Neuronal Activity Associated with Several Forms of Epilepsy
- Licensed from Xenon Pharmaceuticals

NEUROCRINE® BIOSCIENCES

*Investigational and not approved in any country

R&D *Transformation* Will Deliver A New Medicine Every Two Years

Multimodality
R&D innovation engine

Mid-stage pipeline **focused on clinically or genetically validated targets**

Commitment to **R&D Sustainability**



Target level of productivity each year (On Average)

For this steady-state portfolio

1 NEW MEDICINE EVERY 2 YEARS

NEUROCRINE® BIOSCIENCES

Our Pipeline Tomorrow – 18 Programs

End of 2025

Modality Key

Small Molecule | Peptide | Antibody | Gene Therapy

Study Status Key

Current Study | Study Initiating

PROGRAM (TARGET)	MODALITY	THERAPEUTIC AREA	INDICATION	PHASE 1	PHASE 2	PHASE 3
valbenazine (VMAT2 Inhibitor)	Small Molecule	Neuropsychiatry	Adjunctive Treatment of Schizophrenia	Current Study	Current Study	Current Study
valbenazine (VMAT2 Inhibitor)	Small Molecule	Neurology	Dyskinetic Cerebral Palsy	Current Study	Current Study	Current Study
Osavampator / NBI-'845 (AMPA)	Small Molecule	Neuropsychiatry	Inadequate Response to Treatment in Major Depressive Disorder	Current Study	Current Study	Study Initiating
NBI-'568 (M4 Agonist)	Small Molecule	Neuropsychiatry	Schizophrenia	Current Study	Current Study	Study Initiating
NBI-'770 (NMDA NR2B NAM)	Small Molecule	Neuropsychiatry	Major Depressive Disorder	Current Study	Current Study	
NBI-'568 (M4 Agonist)	Small Molecule	Neuropsychiatry	Bipolar Mania	Current Study	Current Study	
NBI-'570 (M1/M4 Agonist)	Small Molecule	Neuropsychiatry	Schizophrenia-CNS Indications	Current Study	Current Study	
NBI-'567 (M1 Agonist)	Small Molecule	Neuropsychiatry	CNS Indications	Current Study		
NBI-'569 (M4 Agonist)	Small Molecule	Neuropsychiatry	CNS Indications	Current Study		
NBI-'986 (M4 Antagonist)	Small Molecule	Neurology	Movement Disorders	Current Study		
NBI-'890 (VMAT2 Inhibitor)	Small Molecule	Neuropsychiatry	CNS Indications	Current Study		
NBI-'355 (Nav1.2/1.6)	Small Molecule	Neurology	Epilepsy	Study Initiating		
NBI-'675 (VMAT2 Inhibitor)	Small Molecule	Neuropsychiatry	CNS Indications	Study Initiating		
NBIP-'1435 (CRF_1 Antagonist)	Peptide	Neuroendocrinology	Congenital Adrenal Hyperplasia	Study Initiating		
Neuroendocrinology Target	Peptide	Neuroendocrinology	Metabolic Disorders	Study Initiating		
Neuroimmunology Target	Antibody	Neuroimmunology	CNS/Immunology Indications	Study Initiating		
NBIB-'223 (Frataxin)	Gene Therapy	Neurology	Friedreich's Ataxia	Study Initiating		
NBIB-'233 (GBA1)	Gene Therapy	Neurology	Parkinson's Disease / Gaucher Disease	Study Initiating		

NEUROCRINE® BIOSCIENCES

Well-Positioned for Sustained & Long-Term Growth

COMMERCIAL*

INGREZZA® (valbenazine) capsules

TARDIVE DYSKINESIA AND HUNTINGTON'S DISEASE CHOREA

Crenessity™ (crinecerfont)

CLASSIC CONGENITAL ADRENAL HYPERPLASIA

RESEARCH & DEVELOPMENT

- Neurology
- Neuroendocrinology
- Neuropsychiatry
- Neuroimmunology

Therapeutic Area Diversification

Robust and Sustainable Pipeline

Multiple Compounds in Mid- to Late-Stage Studies

Rapidly Growing Early-Stage Portfolio

STRONG FINANCIAL POSITION

$2.50 - $2.60 Billion

2025 INGREZZA Annual Net Sales Guidance

~$1.8B

Cash and Investments as of 12/31/2024†

Strong Balance Sheet

Durable Cash Flows

Attractive P&L Profile

NEUROCRINE® BIOSCIENCES

*Products commercialized by Neurocrine Biosciences, Inc. in the U.S.

†On 10/31/24, Neurocrine entered into a $300 million accelerated share repurchase plan which terminated in the first quarter of 2025.

GAAP to Non-GAAP Reconciliations

NEUROCRINE® BIOSCIENCES

You Deserve Brave Science®

NEUROCRINE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in millions, except per share data)	Three Months Ended December 31, 2024	Three Months Ended December 31, 2023	Twelve Months Ended December 31, 2024	Twelve Months Ended December 31, 2023
Revenues:				
Net product sales	$ 621.2	$ 507.2	$ 2,330.6	$ 1,860.6
Collaboration revenue	6.5	8.0	24.7	26.5
Total revenues	627.7	515.2	2,355.3	1,887.1
Operating expenses:				
Cost of revenues	9.3	8.5	34.0	39.7
Research and development	185.6	137.5	731.1	565.0
Acquired in-process research and development	3.0	—	12.5	143.9
Selling, general, and administrative	287.8	218.9	1,007.2	887.6
Total operating expenses	485.7	364.9	1,784.8	1,636.2
Operating income	142.0	150.3	570.5	250.9
Other income (expense):				
Unrealized (loss) gain on equity investments	(1.9)	29.0	(37.1)	28.4
Charges associated with convertible senior notes	—	—	(138.4)	—
Investment income and other, net	22.5	18.9	91.0	52.8
Total other income (expense), net	20.6	47.9	(84.5)	81.2
Income before provision for income taxes	162.6	198.2	486.0	332.1
Provision for income taxes	59.5	50.5	144.7	82.4
Net income	$ 103.1	$ 147.7	$ 341.3	$ 249.7
Earnings per share, basic	$ 1.03	$ 1.50	$ 3.40	$ 2.56
Earnings per share, diluted	$ 1.00	$ 1.44	$ 3.29	$ 2.47
Weighted average common shares outstanding, basic	100.0	98.4	100.4	97.7
Weighted average common shares outstanding, diluted	102.9	102.3	103.7	101.0

NEUROCRINE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)	December 31, 2024	December 31, 2023
Cash, cash equivalents, and marketable securities	$ 1,076.1	$ 1,031.6
Other current assets	648.6	575.4
Total current assets	1,724.7	1,607.0
Deferred tax assets	485.7	362.6
Marketable securities	739.5	687.5
Right-of-use assets	509.4	276.5
Equity investments	124.8	161.9
Property and equipment, net	82.6	70.8
Intangible assets, net	36.5	35.5
Other noncurrent assets	15.5	49.6
Total assets	$ 3,718.7	$ 3,251.4
Convertible senior notes	$ —	$ 170.1
Other current liabilities	507.7	484.7
Total current liabilities	507.7	654.8
Noncurrent operating lease liabilities	455.1	258.3
Other noncurrent liabilities	166.2	106.3
Stockholders' equity	2,589.7	2,232.0
Total liabilities and stockholders' equity	$ 3,718.7	$ 3,251.4

NEUROCRINE BIOSCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS

(unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in millions, except per share data)	2024	2023	2024	2023
GAAP net income [1]	$ 103.1	$ 147.7	$ 341.3	$ 249.7
Adjustments:				
Stock-based compensation expense - R&D	21.2	13.2	68.8	68.0
Stock-based compensation expense - SG&A	45.2	24.9	126.7	126.3
Charges associated with convertible senior notes [2]	—	—	138.4	—
Vacated legacy campus facility costs, net of sublease income [3]	1.0	—	18.0	—
Non-cash amortization related to acquired intangible assets	0.9	0.8	3.6	3.5
Changes in fair values of equity investments [4]	1.9	(29.0)	37.1	(28.4)
Other	—	0.1	0.3	4.6
Income tax effect related to reconciling items [5]	0.1	—	(77.9)	(33.7)
Non-GAAP net income [1]	$ 173.4	$ 157.7	$ 656.3	$ 390.0
Diluted earnings per share:				
GAAP	$ 1.00	$ 1.44	$ 3.29	$ 2.47
Non-GAAP	$ 1.69	$ 1.54	$ 6.33	$ 3.86

1. Twelve months ended December 31, 2024 reflect $71.7 million of expense for development milestones achieved under collaborations and $12.5 million of IPR&D expense for payments of upfront fees. Twelve months ended December 31, 2023 reflect $143.9 million of IPR&D expense related to expansion of strategic partnership with Voyager Therapeutics, Inc.
2. Reflects charges associated with the settlement of convertible senior notes conversions.
3. Reflects impairment charges and other costs associated with our vacated legacy campus facilities, net of sublease income, as we transition to occupy our new campus facility.
4. Reflects periodic fluctuations in the fair values of equity investments.
5. Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance and adjustments to exclude tax benefits or expenses associated with charges associated with convertible senior notes and non-cash stock-based compensation.

NEUROCRINE BIOSCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP EXPENSES
(unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in millions)	2024	2023	2024	2023
GAAP cost of revenues	$ 9.3	$ 8.5	$ 34.0	$ 39.7
Adjustments:				
Non-cash amortization related to acquired intangible assets	0.9	0.8	3.6	3.5
Non-GAAP cost of revenues	$ 8.4	$ 7.7	$ 30.4	$ 36.2

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in millions)	2024	2023	2024	2023
GAAP R&D	$ 185.6	$ 137.5	$ 731.1	$ 565.0
Adjustments:				
Stock-based compensation expense	21.2	13.2	68.8	68.0
Non-GAAP R&D	$ 164.4	$ 124.3	$ 662.3	$ 497.0

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in millions)	2024	2023	2024	2023
GAAP SG&A	$ 287.8	$ 218.9	$ 1,007.2	$ 887.6
Adjustments:				
Stock-based compensation expense	45.2	24.9	126.7	126.3
Vacated legacy campus facility costs, net of sublease income	1.0	—	18.0	—
Other	—	—	—	3.9
Non-GAAP SG&A	$ 241.6	$ 194.0	$ 862.5	$ 757.4

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in millions)	2024	2023	2024	2023
GAAP other income (expense), net	$ 20.6	$ 47.9	$ (84.5)	$ 81.2
Adjustments:				
Charges associated with convertible senior notes	—	—	138.4	—
Changes in fair values of equity investments	1.9	(29.0)	37.1	(28.4)
Other	—	0.1	0.3	0.7
Non-GAAP other income, net	$ 22.5	$ 19.0	$ 91.3	$ 53.5

Advancing Life-Changing Discoveries in Neuroscience

Neurocrine Biosciences (Nasdaq: NBIX)
Q4 and Year-End 2024 Earnings Presentation
February 6, 2025

NEUROCRINE® BIOSCIENCES
You Deserve Brave Science®